EMA Write PMS API Implementation Guide - Enrichments
1.0.0 - ci-build

EMA Write PMS API Implementation Guide - Enrichments - Local Development build (v1.0.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 Examples
... 3 Artifacts Summary
.... 3.1 EMA Write API ActivityDefinition
.... 3.2 EMA Write API Marketing Regulated Authorization
.... 3.3 EMA Write API MedicinalProductDefinition
.... 3.4 EMA Write API PackagedProductDefinition
.... 3.5 EMA Write PMS API Bundle
.... 3.6 EMA AdditionalMonitoringIndicator boolean CodeableConcept
.... 3.7 EMA Application Identifier Number
.... 3.8 EMA ATC Coding
.... 3.9 EMA Coding
.... 3.10 EMA Coding Restrictions
.... 3.11 EMA Data Carrier Identifier
.... 3.12 EMA Duration
.... 3.13 EMA EURD Identifier
.... 3.14 EMA Generic ReferentialTerm CodeableConcept
.... 3.15 EMA Generic ReferentialTerm CodeableConcept restrictions
.... 3.16 EMA Genetically Modified Organisms CodeableConcept
.... 3.17 EMA Identifier Restrictions
.... 3.18 EMA Identifier Restrictions
.... 3.19 EMA Legal Basis CodeableConcept
.... 3.20 EMA Light ATC CodeableConcept
.... 3.21 EMA Manufacturing Authorization Number Identifier
.... 3.22 EMA Marketing Authorization Identifier
.... 3.23 EMA Master File Identifier
.... 3.24 EMA MP Identifier
.... 3.25 EMA PC Identifier
.... 3.26 EMA Period
.... 3.27 EMA Period restrictions
.... 3.28 EMA Product Category CodeableConcept
.... 3.29 EMA Qualified Person Type CodeableConcept
.... 3.30 EMA Quantity
.... 3.31 EMA Ratio
.... 3.32 EMA Subject Restrictions
.... 3.33 EMA Subject Restrictions
.... 3.34 EMA XEVMPD Product CodeableConcept
.... 3.35 The MPD Name Part Type Coding
.... 3.36 Authorised Dose Form
.... 3.37 CodeSystemName
.... 3.38 Date of Update extension
.... 3.39 Language
.... 3.40 Marketing Status Reason
.... 3.41 MedicinalProductDefiniton - MasterFile
.... 3.42 Regulated Authorization - Date of First Authorisation
.... 3.43 Regulated Authorization - International Birth Date
.... 3.44 Regulated Authorization - Paediatric - Reference Country
.... 3.45 Risk of Supply Shortage
.... 3.46 Risk of Supply Shortage Comment
.... 3.47 Submission Date extension
.... 3.48 TermVersion
.... 3.49 The ATC Pending Extension
.... 3.50 The Comparator Extension
.... 3.51 The Complies with directive Extension
.... 3.52 The Ingredient Annex 5.10 Extension
.... 3.53 The Ingredient Annex 5.11 Extension
.... 3.54 The Ingredient Annex 5.20 Extension
.... 3.55 The Ingredient Annex 5.23 Extension
.... 3.56 The Ingredient Documentation Extension
.... 3.57 The Ingredient's Origin of Substance Extension
.... 3.58 The Operation Extension
.... 3.59 The Package Shelf Life Duration Extension
.... 3.60 Additional Monitoring Indicator
.... 3.61 Application Submission Type
.... 3.62 Authorised Dose Form
.... 3.63 Combined Pharmaceutical Dose Form
.... 3.64 Country
.... 3.65 Data Classification
.... 3.66 Documentation
.... 3.67 Domain
.... 3.68 Genetically Modified Organism
.... 3.69 Ingredient Role
.... 3.70 Language
.... 3.71 Legal Status of Supply
.... 3.72 Manufacturing Activity
.... 3.73 Marketing and Manufacturing types
.... 3.74 Marketing Status
.... 3.75 Marketing Status Reason
.... 3.76 Master File Identifier Type
.... 3.77 Master File Type
.... 3.78 Master File Type + DocumentType
.... 3.79 Material
.... 3.80 Medicinal Product Name Part Type
.... 3.81 Medicinal Product Type
.... 3.82 Packaging
.... 3.83 Paediatric Use Indicator
.... 3.84 Pharmaceutical Dose Form
.... 3.85 Product Category
.... 3.86 Product Cross Reference Type
.... 3.87 Promotion
.... 3.88 Quantity Operator
.... 3.89 Regulatory Authorization Registration Procedure
.... 3.90 Regulatory Entitlement Status
.... 3.91 Regulatory Entitlement Type
.... 3.92 Shelf Life Type
.... 3.93 Special Precautions For Storage
.... 3.94 Substance Origin
.... 3.95 Supply
.... 3.96 Unit of Measurement
.... 3.97 Units of Presentation
.... 3.98 XEVMPD medicinal product type
.... 3.99 XEVMPD medicinal product type
.... 3.100 Additional Monitoring Indicator
.... 3.101 Application Submission Type
.... 3.102 Combination Package
.... 3.103 Combined Pharmaceutical Dose Form
.... 3.104 Combined Term
.... 3.105 Contact Type
.... 3.106 Country
.... 3.107 Data Classification
.... 3.108 Document Type
.... 3.109 Documentation
.... 3.110 Domain
.... 3.111 Domain
.... 3.112 Domain
.... 3.113 Genetically Modified Organism
.... 3.114 Ingredient Role
.... 3.115 Legal Status From the Supply
.... 3.116 Manufacturing Activity Value Set
.... 3.117 Marketing Authorisation Application Legal Basis
.... 3.118 Marketing Status
.... 3.119 Master File Identifier Type
.... 3.120 Master File Type
.... 3.121 Material
.... 3.122 Medicinal Product Name Part Type
.... 3.123 Medicinal Product Type
.... 3.124 Paediatric Use Indicator
.... 3.125 Pharmaceutical Dose Form
.... 3.126 Product Category
.... 3.127 Product Cross Reference Type
.... 3.128 Promotion
.... 3.129 Quantity Operator
.... 3.130 Reason for Marketing Unavailability
.... 3.131 Record Status
.... 3.132 Regulatory Authorization Registration Procedure
.... 3.133 Regulatory Entitlement
.... 3.134 Regulatory Entitlement Status
.... 3.135 Shelf Life Type
.... 3.136 Special Precautions for Storage
.... 3.137 Substance Origin
.... 3.138 Supply
.... 3.139 Unit Of Measurement Value Set
.... 3.140 Units Of Presentation
.... 3.141 XEVMPD Medicinal Product Type
.... 3.142 1. Get Product Bundle
.... 3.143 2. Change pack size
.... 3.144 3. Change pack size (response)
.... 3.145 4. Add manufacturing operation
.... 3.146 5. Add manufacturing operation (response)
.... 3.147 ActivityDefinition
.... 3.148 DocumentReference
.... 3.149 DocumentReference
.... 3.150 Organization
.... 3.151 PractitionerRole